Clinical efficacy of simvastatin in treating hyperlipidemia in the type 2 diabetes
Wu Jichuan, Zhang Xuejun, Li Pengqiou, Lu Yuecan (Department of Endocrinology, The provincal People Hospital of Sichuan, Chengdu 610071)
AIM: To evaluate the curative efficacy and safety of treating the type 2 diabetic hyperlipidemia with simvastatin 20 mg/tablet. METHODS: Sixty patients of type 2 diabetes hyperlipidemia were divided randomly into 2 groups. Thirty patients separately were given simvastatin orally 5 mg/tablet (LDL) or 20 mg/tablet in evening for 4 wk. RESULTS: Simvastatin 20 mg/tablet reduced serum total cholesterol (TC) 33%, reduced low density lipoprotein (LDL) 46%, reduced triglycerides (TG) 26%, rose high density lipoprotein (HDL) 21%, and reduced TC/HDL C 44%. Comparasion of 2 groups, area of reduced TG and LDL C and area of rose HDL C had remarkable differences ( P 0 01), area of reduced TC had no remarkable differences ( P 0 05). It had no effect on blood glucose. CONCLUSION: Simvastatin 20 mg/tablet is one of the safe and effective drugs to treat hyperlipidemia of the type 2 diabetes.
【CateGory Index】： R587.1